3-(4-(1H-imidazol-1-ylmethyl)phenyl)-2-propenoic acid,
4-(1-imidazoylmethyl)cinnamic acid,
OKY 046,
OKY-046,
ozagrel,
ozagrel, monohydrochloride,
ozagrel, monohydrochloride, (E)-isomer,
sodium ozagrel,
ozagrel hydrochloride,
OZAGREL HCl,
78712-43-3,
UNII-W222U960HS,
OKY-046,
CHEBI:31954,
W222U960HS,
(E)-3-(4-((1H-Imidazol-1-yl)methyl)phenyl)acrylic acid hydrochloride,
(E)-3-(4-(1H-Imidazol-1-ylmethyl)phenyl)-2-propenoic acid hydrochloride,
Ozagrel hydrochloride hydrate,
CPD000469164,
(E)-3-[4-(imidazol-1-ylmethyl)phenyl]prop-2-enoic acid hydrochloride,
DSSTox_CID_25506,
DSSTox_RID_80920,
DSSTox_GSID_45506,
74003-18-2,
CHEMBL542549,
2-Propenoic acid, 3-(4-(1H-imidazol-1-ylmethyl)phenyl)-, monohydrochloride, (E)-,
SMR000469164,
OKY 046 hydrochloride,
OKY-046 hydrochloride,
SR-01000597793,
ozagrel-hydrochloride,
OKY046 hydrochloride,
ozagrel, monohydrochloride,
NCGC00016937-01,
CAS-78712-43-3,
OKY-046 HCl,
SCHEMBL36182,
SCHEMBL36183,
MLS001401435,
MLS002222319,
AC1O5P37,
DTXSID9045506,
C13H12N2O2.HCl.H2O,
HMS1571C19,
HMS3676F19,
BCP09493,
Tox21_110693,
BN0402,
MFCD06795644,
s2067,
AKOS015895402,
Tox21_110693_1,
CCG-100969,
NC00219,
ozagrel, monohydrochloride, (E)-isomer,
NCGC00025195-06,
AN-36668,
DS-11967,
SAM001246593,
SC-22456,
AB2000471,
LS-123661,
TL8005361,
B2116,
O0419,
SW197369-4,
A11742,
C13144,
A839477,
I06-0662,
SR-01000597793-1,
SR-01000597793-4,
trans-4-[(1-Imidazolyl)methyl]cinnamic Acid Hydrochloride,
(E)-3-[4-(Imidazol-1-ylmethyl)phenyl]propenoic Acid Hydrochloride,
(2E)-3-[4-(1H-Imidazol-1-ylmethyl)phenyl]-2-propenoic acid hydrochloride,
(E)-3-[4-(1-imidazolylmethyl)phenyl]-2-propenoic acid hydrochloride,
(E)-3-[4-(Imidazol-1-ylmethyl)phenyl]propenoic Acid Hydrochloride / trans-4-[(1-Imidazolyl)methyl]cinnamic Acid Hydrochloride,
2-Propenoic acid, 3-(4-(1H-imidazol-1-ylmethyl)phenyl)-, monohydrochloride, monohydrate, (E)-,
null,
OKY 046,
C13-H12-N2-O2.Cl-H,
ACN-048764,
CID6438130,
CS-O-02027,
Ozagrel hydrochloride hydrate, 99%, a selective thromboxane A(2) synthetase inhibitor - 1G 1g,